When Pfizer Inc. chief executive officer Jeffrey Kindler explained why he was spending $68 billion to acquire rival Wyeth, he said he was dazzled by the company's "robust pipeline of biopharmaceutical candidates."
Trending
When Pfizer Inc. chief executive officer Jeffrey Kindler explained why he was spending $68 billion to acquire rival Wyeth, he said he was dazzled by the company's "robust pipeline of biopharmaceutical candidates."
